更新于：2024-05-01

APOH

apolipoprotein H

更新于：2024-05-01

基本信息

别名

Activated protein C-binding protein、Anticardiolipin cofactor、APC inhibitor

+ [9]

简介

Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells.

关联

项与 APOH 相关的药物

OX-1406

靶点

APOH

作用机制

APOH modulators

在研机构

Aura Biopharm AS

原研机构

OncoNOx ApS

在研适应症

抗磷脂综合征

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期1800-01-20

100 项与 APOH 相关的临床结果

登录后查看更多信息

100 项与 APOH 相关的转化医学

登录后查看更多信息

0 项与 APOH 相关的专利（医药）

登录后查看更多信息

2,612

项与 APOH 相关的文献（医药）

2024-02-21·International journal of laboratory hematology

The lupus anticoagulant titer is associated with elevated antiphosphatidylserine/prothrombin immunoglobulin-M isotype antibody levels.

Article

作者: Abdulrahman Saadalla ; Dong Chen ; Melissa Stuart ; Rajiv Pruthi ; Nahla Heikal ; Melissa Snyder ; Aneel Ashrani ; Jansen Seheult

BACKGROUND:

Clot based assays used for lupus anticoagulant (LAC) detection are typically interpreted in a qualitative fashion and may not reflect LAC potency. In this cross-sectional study, we describe a method for quantifying the LAC titer using serial (dependent) two-fold dilutions in normal pooled plasma.

METHODS:

Serial dilutions of 51 residual plasma samples from 50 patients were tested using the Russell's viper venom screening time (DRVVT) and activated partial thromboplastin screening time (APTT) methodologies. The measured clotting times and the corresponding dilution factors were then used to derive a four-parameter logistic model. The LAC titer for each patient was interpolated as the sample dilution that corresponds to the upper reference interval limit of the corresponding assay.

RESULTS:

Calculated APTT and DRVVT LAC titers displayed a strong linear correlation (R² = 0.84) between each other, but not with the degree of prolongation of the APTT/DRVVT screening time in the neat undiluted samples. Using data driven partitioning, patients could be grouped into low (<10) or high (≥10) DRVVT LAC titer. There were no significant differences in anticardiolipin (aCL) or anti-beta 2 glycoprotein 1 (aB2GPI) antibody levels or prevalence of thromboembolic events between low and high LAC titer groups. In contrast, antiphosphatidylserine/prothrombin (aPS/PT) IgM antibody levels, but not IgG, were significantly higher in the high LAC titer group.

CONCLUSIONS:

The degree of prolongation of the APTT/DRVVT screening time is not correlated with the LAC titer. Only aPS/PT IgM antibodies levels were strongly correlated with the LAC titers. Additional studies are warranted to determine clinical implications of high LAC titers.

2024-02-13·Gene

Evaluation of BG, NPR1, and PAL in cotton plants through Virus Induced gene silencing reveals their role in whitefly stress.

Article

作者: Aiman Ehsan ; Khurram Tanveer ; Maryam Azhar ; Rubab Zahra Naqvi ; Mahnoor Jamil ; Shahid Mansoor ; Imran Amin ; Muhammad Asif

Whitefly is one of the most hazardous insect pests that infests a wide range of host plants and causes huge damage to crop worldwide. In order to engineer plants resilient to whitefly stress, it is important to identify and validate the responsive genes by exploring the molecular dynamics of plants under stress conditions. In this study three genes BG, NPR1, and PAL genes have been studied in cotton for elucidating their role in whitefly stress response. Initially, insilico approach was utilized to investigate the domains and phylogeny of BG, NPR1 and PAL genes and found out that these genes showed remarkable resemblance in four cotton species Gossypium hirsutum, G. barbadense, G. arboreum, and G. raimondii. In BG proteins the main functional domain was X8 belonging to glycohydro superfamily, in NPR1 two main functional domains were BTB_POZ at N terminal and NPR1_like_C at C terminal. In PAL functional domain PLN was found which belongs to Lyase class I superfamily. The promoter analysis of these genes displayed enrichment of hormone, stress and stimuli responsive cis elements. Through Virus Induced Gene Silencing (VIGS), these genes were targeted and kept under whitefly infestation. Overall, the whitefly egg and nymph production were observed 60-70% less on gene down regulated plants as compared to control plants. The qPCR-based expression analysis of certain stress-responsive genes showed that in BG down regulated plants the elevated expression of these whitefly responsive genes was detected, in NPR1 down regulated plants JAZ1 and HSP were found up regulated, ERF1 and WRKY40 didn't show significant differential expression, while MAPK6 was slightly down regulated. In PAL down regulated plants ERF1 and JAZ1 showed elevated expression while others didn't show significant alternation. Differential expression in gene down-regulated plants showed that whitefly responsive genes act in a complex inter signaling pathway and their expression impact each other. This study provides valuable insight into the structural and functional analysis of important whitefly responsive genes BG, NPR1, and PAL. The results will pave a path to future development of whitefly resilient crops.

2024-02-12·Journal of environmental management

Co-applied biochar and PGPB promote maize growth and reduce CO₂ emission by modifying microbial communities in coal mining degraded soils.

Article

作者: Yiping Zou ; Xinli Chen ; Shuyue Zhang ; Ben Zhang ; Yunxing Bai ; Tao Zhang ; Jianli Jia

Coal mining is one of the human activities that has the greatest impact on the global carbon (C) cycle and biodiversity. Biochar and plant growth-promoting bacteria (PGPB) have been both used to improve coal mining degraded soils; however, it is uncertain whether the effects of biochar application on soil respiration and microbial communities are influenced by the presence or absence of PGPB and soil nitrogen (N) level in coal mining degraded soils. A pot experiment was carried out to examine whether the effects of biochar addition (0, 1, 2 and 4% of soil mass) on soil properties, soil respiration, maize growth, and microbial communities were altered by the presence or absence of PGPB (i.e. Sphingobium yanoikuyae BJ1) (0, 200 mL suspension (2 × 10⁶ colony forming unit (CFU) mL^-1)) and two soil N levels (N0 and N1 at 0 and 0.2 g kg^-1 urea- N, respectively). The results showed the presence of BJ1 enhanced the maize biomass relative to the absence of BJ1, particularly in N1 soils, which was related to the discovery of Lysobacter and Nocardioides that favor plant growth in N1 soils. This indicates a conversion in soil microbial communities to beneficial ones. The application of biochar at a rate of 1% decreased the cumulative CO₂ regardless of the presence or absence of BJ1; BJ1 increased the β-glucosidase (BG) activities, and BG activities were also positively correlated with RB41 strain with high C turnover in N1 soils, which indicates that the presence of BJ1 improves the C utilization rates of RB41, decreasing soil C mineralization. Our results highlight that biochar addition provided environmental benefits in degraded coal mining soils, and the direction and magnitude of these effects are highly dependent on the presence of PGPB and the soil N level.

项与 APOH 相关的新闻（医药）

2024-03-24

·AIDD Pro

【第一百一十九期】AI+药物研发领域一周资讯

前言AIDD Pro 根据国内外各大网站以及人工智能药物设计主流新闻网站及公众号，从 AIDD会议、AIDD招聘，重大科研进展、行业动态、最新报告发布等角度，分析挖掘了每周人工智能辅助药物设计领域所发生的、对领域技术发展产生重大推动作用的事件，旨在帮助 AIDD领域研究人员和业内人士及时追踪最新科研动态、洞察前沿热点。如果您觉得符合以上要求的内容我们有遗漏或者更好建议，欢迎后台留言。科研进展2024年3月23日【神经网络】J. Chem. Inf. Model. | 利用横向相互作用脉冲神经网络发现靶向3CL蛋白酶的共价先导化合物2024年3月22日【分子性质预测】J. Chem. Inf. Model. | LGGA-MPP：分子性质预测的局部几何引导图注意2024年3月22日【SARS-CoV-2】ACS Omega | 通过基因组尺度的重编程代谢模型和治疗策略揭示SARS-CoV-2对肝脏代谢的影响2024年3月21日【分子对接】J. Chem. Inf. Model. | AGT介导的dG-dC交联修复对氯乙基亚硝基源耐药的机制：分子对接、MD模拟和ONIOM (QM/MM)研究2024年3月21日【药物协同预测】J. Chem. Inf. Model. | CFSSynergy：结合基于特征和基于相似性的药物协同预测方法2024年3月21日【药物递送】Bioconjugate Chem. | 用于细胞内药物递送的生物可还原的两亲性超支化聚合物-药物偶联物具体信息，请滑动下方文字1.【神经网络】共价药物具有非共价药物无法匹配的优势，而共价对接是筛选共价先导化合物的重要方法。然而，由于共价对接需要确定化合物的共价反应类型，因此共价对接很难大规模筛选共价化合物。本文提出利用横向相互作用脉冲神经网络的深度学习构建共价先导化合物筛选模型，快速筛选共价先导化合物。我们以SARS-CoV-2的3CL蛋白酶(3CL Pro)为筛选靶点，构建了两个基于LISNN的分类模型来预测化合物的共价结合和抑制活性。两种分类模型分别在以半胱氨酸(Cys)为目标的共价复合物数据集和以3CL Pro为目标的化合物抑制活性数据集上进行训练，预测准确率均较好(ACC > 0.9)。然后用6个共价结合筛选模型和12个抑制活性筛选模型对筛选化合物文库进行筛选。对32种化合物的抑制活性进行了测试，结果表明，最佳化合物抑制sars - cov - 23cl Pro的IC50值为369.5 nM。进一步分析表明，二硫苏糖醇可以影响化合物对3CL Pro的抑制活性，表明该化合物可能与3CL Pro共价结合。选择性实验表明，该化合物对组织蛋白酶l具有良好的靶向选择性，这些相关性实验证明了共价先导化合物筛选模型的合理性。最后，进行共价对接以证明该化合物与3CL Pro的结合构象。源代码可以从GitHub存储库(https://github.com/guzh970630/Screen_Covalent_Compound_by_LISNN)获得。链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.3c01900DOI：https://doi.org/10.1021/acs.jcim.3c019002.【分子性质预测】分子性质预测是药物发现的一项基本任务。随着深度学习的快速发展，预测分子性质的计算方法越来越受欢迎。然而，这些现有的方法往往忽略了分子的三维信息，而这在分子表征学习中是至关重要的。在过去的几年里，人们提出了几种利用三维分子图预训练和二维分子图微调来利用几何信息的自监督学习方法。这些方法大多是基于分子的整体几何结构，在捕获局部结构和局部可解释性方面仍然存在挑战。为此，我们提出了局部几何引导图注意(LGGA)，它将局部几何集成到图神经网络(gnn)的注意机制和消息传递中。LGGA引入了一种新的方法来模拟分子，增强了模型捕捉复杂局部结构细节的能力。在不同数据集上的实验表明，局部几何的集成对改进结果有显著的影响，并且我们的模型优于最先进的分子性质预测方法，建立了其作为药物发现和相关领域的有前途的工具的潜力。链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.3c02058DOI：https://doi.org/10.1021/acs.jcim.3c020583.【SARS-CoV-2】基因组尺度代谢模型(GEMs)是一种很有前途的计算工具，有助于阐明宿主-病毒在系统水平上的相互作用，并制定针对病毒感染的治疗策略。本研究利用人肝细胞和SARS-CoV-2的整合GEMs研究了SARS-CoV-2对肝脏代谢的影响。它们是利用转录组数据为未感染和感染的肝细胞生成的。报告代谢物分析显示，由于SARS-CoV-2感染，涉及外源性药物、药物、花生四烯酸和白三烯代谢的几种代谢物发生了显著的转录变化。通量平衡分析和最小化代谢调节方法揭示了病毒在脂肪酸、甘油磷脂、鞘脂胆固醇、叶酸代谢、胆汁酸生物合成和肉毒碱穿梭等方面可能引起的肝细胞重编程。反应敲除分析提供了糖酵解、氧化磷酸化、嘌呤代谢和活性氧解毒子系统中的关键反应。计算分析还表明，多巴胺、葡萄糖胺、d -木糖、半胱氨酸和(R)-3-羟基丁酸盐有助于减轻病毒感染。从本质上讲，重建的宿主病毒GEM有助于我们理解代谢编程，并制定对抗SARS-CoV-2的治疗策略。链接网址：https://pubs.acs.org/doi/10.1021/acsomega.4c00392DOI：https://doi.org/10.1021/acsomega.4c003924.【分子对接】氯乙基亚硝基源(CENUs)是治疗癌症的重要化学药物。它们通过形成两个o6 -烷基鸟嘌呤中间体o6 -氯乙基鸟嘌呤(O6-ClEtG)和N1, o6 -乙醇鸟嘌呤(N1,O6-EtG)诱导DNA链间交联(ICLs)发挥抗癌活性。而dna修复酶o6 -烷基鸟嘌呤- dna烷基转移酶(AGT)可以修复o6 -烷基鸟嘌呤损伤，从而阻碍ICLs的形成(dG-dC交联)。本研究通过研究ICL形成的抑制机制，详细阐明AGT介导的CENUs耐药机制。基于对接和MD模拟得到的底物-酶配合物的结构，构建了两个具有不同QM区域大小的ONIOM (QM/MM)模型。该模型具有较大的QM区域，包括AGT活性袋中的底物(O6-ClEtG或N1、O6-EtG)、一个水分子和5个残基(Tyr114、Cys145、His146、Lys165和Glu172)，准确地描述了修复反应，得到的结果与实验结果一致。修复过程包括两个连续的步骤:氢转移到Cys145上形成硫代阴离子和从鸟嘌呤的O6位点转移烷基(限速步骤)。从动力学和热力学的角度来看，N1,O6-EtG的修复比O6-ClEtG的修复更有利。此外，将修复过程与dG-dC交联的形成和o6 -苄基鸟嘌呤(O6-BG)对AGT的抑制进行比较发现，AGT的存在可以有效阻断icl的形成导致耐药性，O6-BG对AGT的抑制在能量上比O6-ClEtG的修复更有利，但不能阻止N1,O6-EtG的修复。因此，有必要在给药前完全消除AGT活性，以提高化疗效果。这项工作为agt介导的CENU耐药机制提供了合理的解释，并将有助于开发新的CENU化疗药物及其用药策略。链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.3c01958DOI：https://doi.org/10.1021/acs.jcim.3c019585.【药物协同预测】药物协同预测在肿瘤治疗中起着至关重要的作用。由于实验方法是劳动密集型和昂贵的，基于计算的方法得到了更多的关注。药物协同作用预测的计算方法有两种:基于特征的和基于相似度的。在基于特征的方法中，主要重点是从药物对和细胞系中提取更多的判别特征以传递给任务预测器。在基于相似性的方法中，所有药物和细胞系之间的相似性被用作特征并输入到任务预测器中。在这项工作中，提出了一种新的方法，称为CFSSynergy，它结合了这两种观点。首先，提取配对药物和细胞系作为输入的判别表示。我们已经将基于变压器的结构用于药物。对于细胞系，我们使用Node2Vec算法创建了蛋白质之间的相似性矩阵。然后，通过将蛋白质-蛋白质相似性矩阵与初始细胞系表示相乘来计算新的细胞系表示。接下来，我们使用对配对药物和细胞系的学习表示来计算独特药物和独特细胞之间的相似性。然后，我们基于相似性特征和学习到的特征计算成对药物和细胞系的新表示。最后，这些特性作为任务预测器提供给XGBoost。我们使用了两个著名的数据集来评估我们提出的方法的性能:DrugCombDB和OncologyScreen。CFSSynergy方法在比较评估中始终优于现有方法。这证实了我们的方法在捕获药物和细胞系之间复杂的协同相互作用方面的有效性，将其与传统的基于相似性或基于特征的方法区分开来。链接网址：https://pubs.acs.org/doi/10.1021/acs.jcim.3c01486DOI：https://doi.org/10.1021/acs.jcim.3c014866.【药物递送】本文报道了以市售的二硫苏糖醇(DTT) (A2)和含有三个活性吡啶二硫化基的易获得的三官能团单体(B3)为原料，采用A2+B3方法合成了一种生物可还原的超支化(HB)聚合物。高效的硫醇活化二硫交换反应生成HB聚合物(Mw = 21000;Đ = 2.3)，主链上有生物可还原的二硫键，hb -聚合物的核心和外围分别有两个不同的官能团，即羟基和吡啶二硫。羟基与喜树碱(CPT)(一种拓扑异构酶抑制剂和已知的抗癌药物)进行聚合后功能化，然后用低聚氧乙烯-硫醇取代末端的吡啶基二硫基团，从而容易获得两亲性HB聚二硫-CPT偶联物(P1)，其载药量非常高，约为40%。P1在水中聚集(高于~ 10 μg/mL)，产生载药纳米颗粒(Dh ~ 135 nm)，显示出谷胱甘肽(GSH)触发的高效释放活性CPT。经gsh处理的P1的质谱分析显示，存在活性CPT药物以及环状单硫代碳酸酯产物，这支持了级联降解机制，包括gsh触发的不稳定二硫键的裂解，随后原位生成的硫醇分子内亲核攻击邻近的碳酸盐键，导致活性CPT药物释放。通过共聚焦荧光显微镜检测，P1纳米颗粒在HeLa细胞中表现出良好的细胞摄取，主要通过内吞机制，导致高效的细胞杀伤(IC50 ~ 0.6 μg/mL)，这从MTT实验和凋亡实验的结果中可以看出。与类似的线性聚合物- cpt缀合物的比较研究表明，超支化聚合物的细胞内药物递送能力更强。链接网址：https://pubs.acs.org/doi/10.1021/acs.bioconjchem.4c00006DOI：https://doi.org/10.1021/acs.bioconjchem.4c00006上下滚动查看更多药企动态2023年3月22日【诺华】诺华first-in-class口服PNH新药获CHMP推荐上市2023年3月22日【卫材】欧盟推迟对阿尔茨海默症Lecanemab的审批2023年3月21日【诺和诺德】欧盟委员会建议批准诺和诺德胰岛素周制剂icodec2023年3月21日【三生国健】首款国产IL-5单抗进入III期阶段2023年3月20日【云顶新耀】云顶新耀IgA肾病新药在新加坡批准上市2023年3月20日【拜耳】健康元引进拜耳口服小分子COPD新药各动态具体信息，请滑动下方文字1.【诺华】3月22日，诺华宣布欧洲药品管理局（EMA）人用药品委员会（CHMP）通过了一项积极意见，建议授予Fabhalta（iptacopan）的上市许可，用于患有溶血性贫血的成人阵发性睡眠性血红蛋白尿症（PNH）。链接网址请戳我2.【卫材】3月22日，卫材宣布，由于欧洲药品管理局（EMA）的程序原因，人用药品委员会（CHMP）对阿尔茨海默症新药leanemab（仑卡奈单抗）上市许可申请（MAA）的审议将重新安排，这就导致EMA对leanemab作出审批决定的时间也会推迟。链接网址请戳我3.【诺和诺德】3月21日，诺和诺德宣布欧洲药品管理局人用医药产品委员会（CHMP）通过了一项积极的意见，建议批准Awiqli（每周一次基础胰岛素icodec）用于治疗成人糖尿病。链接网址请戳我4.【三生国健】3月21日，ClinicalTrials.gov网站显示，三生国健开发的IL-5单抗SSGJ-610启动了III期临床试验，成为了首款进入III期阶段的国产IL-5单抗。链接网址请戳我5.【云顶新耀】3月20日，云顶新耀宣布新加坡卫生科学局（HSA）已批准耐赋康®用于治疗具有疾病进展风险的原发性IgA肾病成人患者。耐赋康®是首个也是唯一一个获得美国食品药品监督管理局完全批准的IgA肾病对因治疗药物，而新加坡是云顶授权区域内继中国内地和中国澳门后的第三个获得耐赋康®新药上市批准的地区，进一步扩大了亚洲患者可及性。链接网址请戳我6.【拜耳】3月20日，健康元宣布其与拜耳就一项小分子抑制剂在国内的开发、商业化和生产的独家许可签署协议，这也是健康元首次从全球领先的跨国公司引进呼吸领域的创新药管线。所涉及的小分子化合物是一种创新的针对慢性阻塞性肺疾病（COPD）的口服药物，其通过抑制脯氨酰内肽酶（PREP）活性，有效阻止了COPD炎症介质的产生。这种独特的作用机制有望带给COPD患者巨大获益，还有望对整体疾病进展产生积极影响。目前已在欧洲成功完成I期临床试验。链接网址请戳我上下滚动查看更多会议信息2024年4月18-19日举办第四届I-RNA小核酸药物深度聚焦峰会2024年6月27-28日上海求实医药咨询有限公司举办ING 2024第七届免疫及基因治疗论坛各会议具体详情和参会方式，请滑动下方文字第四届I-RNA小核酸药物深度聚焦峰会会议时间：2024年4月18日-19日会议地点：苏州会议主旨：破解递送挑战与CMC难点，汇聚最新临床进展与热门研发方向；构建小核酸药物专属交流平台，打造产业闭环，推动国产小核酸药物产业化进程。链接网址请戳我ING 2024第七届免疫及基因治疗论坛主办方：上海求实医药咨询有限公司会议时间：2024年6月27日-28日会议地点：北京会议主旨：聚焦CGT领域开发的核心问题，破除技术壁垒，推动产业不断前进，开启生物医药产业下一个风口！链接网址请戳我上下滚动查看更多版权信息本文内容均由小编收集于公开的各个网络平台，发布的目的仅为了方便大家一站式了解AIDD行业信息，并未对发布源头进行真实性验证。如您发现相关信息有任何版权侵扰或者信息错误，请及时联系AIDD Pro（请添加微信号sixiali_fox59）进行删改处理。原创内容未经授权，禁止转载至其他平台。有问题可发邮件至sixiali@stonewise.cn关注我，更多资讯早知道↓↓↓

上市批准

2024-02-20

·NS Medical Devices

Werfen secures CE mark for Aptiva APS IgG and APS IgM reagents

The Aptiva APS IgG and APS IgM reagents are immunoassays designed for semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM autoantibodies in human serum and citrated plasma Aptiva leverages particle-based multi-analyte technology (PMAT). (Credit: PRNewswire/Werfen) Spanish diagnostics solutions provider Werfen has received the CE mark for its Aptiva Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents. Werfen secured the CE mark under the European Union’s (EU) in-vitro diagnostic medical devices regulation (IVDR). The Aptiva APS IgG and APS IgM reagents are immunoassays that leverage Aptiva particle-based multi-analyte technology (PMAT). They are intended for semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM autoantibodies in human serum and citrated plasma. When used together with other laboratory findings, the IgG and APS IgM reagents will help in the diagnosis of primary and secondary APS. Werfen research and development vice president Michael Mahler said: “Antiphospholipid syndrome is an autoimmune disease that manifests clinically as venous or arterial thrombosis and/or foetal loss and can be challenging to diagnose as its symptoms can mimic those of other conditions. “Early diagnosis is crucial in preventing complications as well as unnecessary procedures and increased healthcare costs. “Aptiva APS IgG and APS IgM deliver expanded information to clinicians to help with the diagnosis and management of patients with autoimmune diseases.” Werfen said that its new Aptiva APS reagents will complement its previous Aptiva Celiac Disease and Connective Tissue Diseases (CTD) Essential reagents. The APS reagents also expand the number of CE-marked analytes detected by Aptiva to 19. Aptiva is designed to target additional autoimmune disease states and has more than 60 analytes in various stages of advanced development. The analytes can potentially improve the accuracy of autoimmune disease diagnosis and support better patient management. The Aptiva system is a fully automated multi-analyte system that represents the next-generation high throughput analysers for the autoimmunity and immunology laboratory. Aptiva uses particle-based multi-analyte technology to deliver up to 120 APS results per hour and allows the laboratory to complete the workload faster with PMAT. Established in 1966, Werfen is a provider of specialised diagnostic instruments, related reagents, and data management solutions for use in hospitals and clinical laboratories. The company’s business focuses on autoimmunity, haemostasis, acute care diagnostics, transfusion, transplant, and original equipment manufacturing (OEM).

免疫疗法诊断试剂

2024-02-19

·PRNewswire

Werfen Receives CE Mark for Aptiva® Antiphospholipid Syndrome Reagents

New Aptiva APS IgG and APS IgM Reagents Enable Early Diagnosis of Antiphospholipid Syndrome in Hard-to-Diagnose Autoimmune Disease SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Werfen today announced it has received CE (Conformité Européenne) mark for its Aptiva® Antiphospholipid Syndrome (APS) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) reagents under the European Union's (EU) In Vitro Diagnostic Medical Devices Regulation (IVDR). Continue Reading Aptiva utilizes particle-based multi-analyte technology (PMAT) The Aptiva APS IgG and APS IgM reagents are immunoassays that utilize Aptiva particle-based multi-analyte technology (PMAT) for the semi-quantitative determination of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein 1 (aβ2GP1) IgG and IgM autoantibodies in human serum and citrated plasma. They are used as an aid in the diagnosis of primary and secondary APS, when used in conjunction with other laboratory findings. "Antiphospholipid syndrome is an autoimmune disease that manifests clinically as venous or arterial thrombosis and/or fetal loss and can be challenging to diagnose as its symptoms can mimic those of other conditions," said Michael Mahler, PhD, Vice President of Research and Development at Werfen. "Early diagnosis is crucial in preventing complications as well as unnecessary procedures and increased healthcare costs. Aptiva APS IgG and APS IgM deliver expanded information to clinicians to help with the diagnosis and management of patients with autoimmune diseases." The new Aptiva APS reagents complement Werfen's previously registered Aptiva Celiac Disease and Connective Tissue Diseases (CTD) Essential reagents and expand the number of CE Marked analytes detected by Aptiva to 19. In addition to the APS, CTD and Celiac Disease assays, Aptiva will target additional autoimmune disease states, and has over 60 analytes in various stages of advanced development. These analytes have the potential to improve the accuracy of autoimmune disease diagnosis and support better patient management. The Aptiva system is a fully automated multi-analyte system that represents the next generation of high throughput analyzers for the autoimmunity and immunology laboratory. Aptiva uses particle-based multi-analyte technology to deliver up to 120 APS results per hour. With PMAT, Aptiva enables the laboratory to complete its workload faster and with minimal hands-on time. About Werfen Werfen (werfen.com) founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company's business lines include Autoimmunity, Hemostasis, Acute Care Diagnostics, Transfusion, Transplant, and Original Equipment Manufacturing (OEM). Werfen's solutions help improve the way patients with autoimmune diseases are diagnosed, monitored, and treated. The autoimmunity portfolio includes Aptiva®, BIO-FLASH®, NOVA View®, and QUANTA-Lyser® 3000 systems, and QUANTA Link® data management solution. The Werfen logo is a trademark of Werfen. Aptiva, QUANTA-Lyser, QUANTA Lite, QUANTA Link, QUANTA Flash, NOVA View, NOVA Lite are registered trademarks of Inova Diagnostics, Inc., a Werfen company, as the legal manufacturer. BIO-FLASH is a registered trademark of Biokit S.A. GEM, Premier, GEM Premier ChemSTAT, GEMweb, iQM, ChemSTAT, HemosIL, ACL, ACL TOP, ACL Elite, ACL AcuStar, ReadiPlasTin, RecombiPlasTin, SynthASil, SynthAFax, ROTEM, Hemochron, VerifyNow and Avoximeter are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners. Photo -